Claris Lifesciences Inc FDA Inspection Record

FEI 3007003961 · Inspections, Form 483s, warning letters and import refusals

Claris Lifesciences Inc is an FDA-inspected facility (FEI 3007003961) located in North Brunswick, NJ, US. RegDataLab tracks 4 FDA inspections at this facility.

What FDA found at this site

Latest inspection
May 18, 2012: No Action Indicated (NAI)
Inspections on record
4 (3 VAI, 1 NAI)
Last OAI inspection
None on record
Warning letters
None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
Recalls as the recalling firm
3, latest Nov 6, 2017

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
May 18, 2012No Action Indicated (NAI)No citations listed
Jun 7, 2010Voluntary Action Indicated (VAI)No citations listed
Feb 2, 2010Voluntary Action Indicated (VAI)Failure to report non-alert ADEs (21 CFR 314.80(c)(2))
Incomplete periodic safety report (21 CFR 314.80(c)(2)(ii)(A))
Incomplete patient information on ICSR (21 CFR 314.80(f)(1))
Jul 13, 2009Voluntary Action Indicated (VAI)Failure to review ADE information (21 CFR 314.80(b))
Failure to develop written procedures (21 CFR 314.80(b))
Late submission of 15-day report (21 CFR 314.80(c)(1)(i))
Failure by applicant to report ADE (21 CFR 314.80(c))
and 1 more

Recalls

Newest first. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Nov 6, 2017Class IIID-0127-2018Ciprofloxacin in Dextrose (5%) Injection, USP 200 mg in 100 mL 5% Dextrose, Rx Only, (2…
Superpotent
Mar 10, 2017Class IID-0613-2017Ciprofloxacin in Dextrose (5%) Injection, USP, 400 mg in 200 mL 5% Dextrose, Rx only… and 3 more products
Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility…
May 31, 2010Class ID-026-2011METROnidazole Injection, USP, 500 mg/100 mL (5 mg/mL), 100 mL SINGLE DOSE CONTAINER bag… and 3 more products
Non-Sterility: The intravenous medication metronidazole may be contaminated with mold, fungus, and/or bacteria.

FDA record score

1 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 16, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

5 records behind this number
RecordDatePoints x age weightAdds
Class II recall D-0613-2017, this FEI as the recalling firmMar 10, 20174 x 0.251
Inspection classified VAIJun 7, 201010 years or older, so it adds no points0
Class I recall D-026-2011, this FEI as the recalling firmMay 31, 201010 years or older, so it adds no points0
Inspection classified VAIFeb 2, 201010 years or older, so it adds no points0
Inspection classified VAIJul 13, 200910 years or older, so it adds no points0

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 16, 2026Newest record Nov 5, 2026Current
Inspection citationsNov 16, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 16, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 16, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 13, 2026Newest record Nov 12, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Claris Lifesciences Inc as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Claris Lifesciences Inc yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Claris Lifesciences Inc
Location
North Brunswick, NJ (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.